BR112016007536A2 - compostos, composições e utilizações correspondentes, para a prevenção e/ou o tratamento de dislipidemias - Google Patents

compostos, composições e utilizações correspondentes, para a prevenção e/ou o tratamento de dislipidemias

Info

Publication number
BR112016007536A2
BR112016007536A2 BR112016007536A BR112016007536A BR112016007536A2 BR 112016007536 A2 BR112016007536 A2 BR 112016007536A2 BR 112016007536 A BR112016007536 A BR 112016007536A BR 112016007536 A BR112016007536 A BR 112016007536A BR 112016007536 A2 BR112016007536 A2 BR 112016007536A2
Authority
BR
Brazil
Prior art keywords
compositions
compounds
treat
prevent
dyslipidemia
Prior art date
Application number
BR112016007536A
Other languages
English (en)
Other versions
BR112016007536B1 (pt
BR112016007536A8 (pt
Inventor
Vandebrouck Clarisse
Ferru-Clement Romain
Ferreira Thierry
Original Assignee
Centre National De La Recherce Scient Cnrs
Univ Poitiers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National De La Recherce Scient Cnrs, Univ Poitiers filed Critical Centre National De La Recherce Scient Cnrs
Publication of BR112016007536A2 publication Critical patent/BR112016007536A2/pt
Publication of BR112016007536A8 publication Critical patent/BR112016007536A8/pt
Publication of BR112016007536B1 publication Critical patent/BR112016007536B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção se refere ao campo da medicina. mais particularmente refere-se a utilização de compostos para prevenir e/ou tratar lipotoxicidade em um indivíduo, especialmente lipotoxicidade por hipóxia. a invenção refere-se mais particularmente a composições, especialmente composições farmacêuticas e suplementos nutricionais, compreendendo tais compostos bem como a utilização destes para prevenir e/ou tratar lipo-intoxicação, especialmente lipo-intoxicação por hipóxia. os compostos e composições da invenção podem, em particular, ser vantajosamente utilizados para prevenir e/ou tratar uma patologia selecionada dentre as patologias pulmonares, em particular, fibrose cística ou uma doença pulmonar obstrutiva crônica.
BR112016007536-6A 2013-10-08 2014-10-08 compostos, composições e utilizações correspondentes, para a prevenção e/ou o tratamento de dislipidemias BR112016007536B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1302334 2013-10-08
FR1302334A FR3011467B1 (fr) 2013-10-08 2013-10-08 Composes et compositions comprenant de tels composes pour la prevention ou le traitement des dyslipidemies
PCT/EP2014/071543 WO2015052237A1 (fr) 2013-10-08 2014-10-08 Composes, compositions et utilisations correspondantes, pour la prevention et/ou le traitement des dyslipidemies

Publications (3)

Publication Number Publication Date
BR112016007536A2 true BR112016007536A2 (pt) 2017-09-26
BR112016007536A8 BR112016007536A8 (pt) 2018-01-30
BR112016007536B1 BR112016007536B1 (pt) 2020-10-13

Family

ID=50023610

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016007536-6A BR112016007536B1 (pt) 2013-10-08 2014-10-08 compostos, composições e utilizações correspondentes, para a prevenção e/ou o tratamento de dislipidemias

Country Status (11)

Country Link
US (2) US9821000B2 (pt)
EP (2) EP3065733B1 (pt)
JP (2) JP6594866B2 (pt)
CN (2) CN105744934B (pt)
AU (2) AU2014333853A1 (pt)
BR (1) BR112016007536B1 (pt)
CA (2) CA2926582C (pt)
ES (2) ES2674869T3 (pt)
FR (1) FR3011467B1 (pt)
PL (1) PL3065732T3 (pt)
WO (2) WO2015052237A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2790700T3 (es) 2005-12-28 2020-10-28 Vertex Pharma Composiciones farmacéuticas de la forma amorfa de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolin-3-carboxamida
US9744542B2 (en) 2013-07-29 2017-08-29 Apeel Technology, Inc. Agricultural skin grafting
WO2016057730A1 (en) 2014-10-07 2016-04-14 Strohmeier Mark Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
ES2784914T3 (es) 2015-05-20 2020-10-02 Apeel Tech Inc Composiciones de extractos de plantas y métodos de preparación de las mismas
EP3349589B1 (en) 2015-09-16 2022-12-14 Apeel Technology, Inc. Method for forming a protective coating by applying fatty acid glyceride compounds to a surface
EP3649860B1 (en) 2015-12-10 2023-02-01 Apeel Technology, Inc. Plant extract compositions for forming protective coatings
EP3407713A1 (en) 2016-01-26 2018-12-05 Apeel Technology, Inc. Method for preparing and preserving sanitized products
CN110087475B (zh) 2016-11-17 2023-04-11 阿比尔技术公司 由植物提取物形成的组合物及其制备方法
EP3955913A4 (en) * 2019-04-16 2023-01-04 Enzychem Lifesciences COMPOSITIONS AND METHODS FOR DIABETES TREATMENT
KR102218540B1 (ko) * 2019-04-16 2021-02-22 주식회사 엔지켐생명과학 모노아세틸디아실글리세롤 화합물을 함유하는 당뇨병 치료용 조성물 및 당뇨병의 치료 방법
MX2022010392A (es) 2020-03-04 2022-09-05 Apeel Tech Inc Productos agricolas recubiertos y metodos correspondientes.
EP4237400A1 (en) 2020-10-30 2023-09-06 Apeel Technology, Inc. Compositions and methods of preparation thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5914520B2 (ja) * 1977-07-29 1984-04-04 カネボウ株式会社 二層型液状シヤンプ−
JPS5953421A (ja) * 1983-02-15 1984-03-28 Ajinomoto Co Inc コレステロ−ル低下または上昇抑制剤
EP0104043A3 (en) * 1982-09-20 1984-06-06 Ajinomoto Co., Inc. Foodstuffs and pharmaceuticals
CA2384679A1 (en) * 1999-09-08 2001-03-15 Srinivasan Venkateshwaran Using quaternary ammonium salts for transdermal drug delivery
CA2402815A1 (en) * 2000-04-03 2001-10-11 3M Innovative Properties Company Dental materials with extendable work time, kits, and methods
IL142537A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of autoimmune diseases
US20030066100A1 (en) * 2001-07-09 2003-04-03 Zoltan Machaty Capacitative calcium entry mechanism in porcine oocytes
AU2002343163A1 (en) * 2001-11-15 2003-05-26 Koninklijke Philips Electronics N.V. High-pressure discharge lamp
US7700583B2 (en) * 2003-04-11 2010-04-20 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
GB0425658D0 (en) * 2004-11-22 2004-12-22 Stanford Rook Ltd Immunotherapeutic agent
US20090124608A1 (en) * 2006-10-16 2009-05-14 Board Of Trustees Of The University Of Arkansas CB2 Receptor Modulators In Neurodegenerative Diseases And Applications Of The Same
US20120128770A1 (en) * 2009-06-24 2012-05-24 Kobenhavns Universitet Treatment of insulin resistance and obesity by stimulating glp-1 release
US20130303466A1 (en) * 2010-10-19 2013-11-14 Elcelyx Therapeutics, Inc. Chemosensory Receptor Ligand-Based Therapies

Also Published As

Publication number Publication date
US10231985B2 (en) 2019-03-19
JP6594866B2 (ja) 2019-10-23
CA2926582C (fr) 2023-07-25
ES2682973T3 (es) 2018-09-24
PL3065732T3 (pl) 2019-03-29
US9821000B2 (en) 2017-11-21
WO2015052237A1 (fr) 2015-04-16
CN105828814B (zh) 2019-04-19
BR112016007536B1 (pt) 2020-10-13
WO2015052433A1 (fr) 2015-04-16
EP3065732B1 (fr) 2018-04-11
JP2016535725A (ja) 2016-11-17
CA2927951C (en) 2022-08-30
JP6502335B2 (ja) 2019-04-17
BR112016007536A8 (pt) 2018-01-30
EP3065733A1 (fr) 2016-09-14
CA2926582A1 (fr) 2015-04-16
US20160287542A1 (en) 2016-10-06
AU2014333853A1 (en) 2016-05-12
ES2674869T3 (es) 2018-07-04
CN105828814A (zh) 2016-08-03
CA2927951A1 (en) 2015-04-16
CN105744934B (zh) 2019-08-20
AU2014333636B2 (en) 2019-12-05
FR3011467A1 (fr) 2015-04-10
US20160256429A1 (en) 2016-09-08
AU2014333636A1 (en) 2016-05-05
EP3065733B1 (fr) 2018-05-30
EP3065732A1 (fr) 2016-09-14
FR3011467B1 (fr) 2016-02-12
JP2016535727A (ja) 2016-11-17
CN105744934A (zh) 2016-07-06

Similar Documents

Publication Publication Date Title
BR112016007536A8 (pt) compostos, composições e utilizações correspondentes, para a prevenção e/ou o tratamento de dislipidemias
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
MA52257A (fr) Compositions pharmaceutiques comprenant blautia et leur administration orale
BR112018015273A2 (pt) derivados de benzimidazol como moduladores de ror-gama
TN2015000278A1 (en) Autotaxin inhibitors
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
EA201890767A1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
BR112014016810A2 (pt) composições e métodos para tratamento de distúrbios metabólicos
MA38399B2 (fr) Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
BR112015022041A2 (pt) derivados substituídos de 3-fenilpropilamina para o tratamento de doenças e distúrbios oftálmicas
PH12016500814A1 (en) Heteroaryl butanoic acid derivatives
MX2013003635A (es) Compuestos de n-heteroarilo.
WO2014151456A3 (en) Treatment of inflammatory diseases
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
IL242143B (en) A pharmaceutical preparation for oral administration for the prevention or treatment of dry eye syndrome, containing rabamifid or its prodrug
BR112017006842A2 (pt) formulação de rapamicina inalável para o tratamento de hipertensão pulmonar
EP3060220A4 (en) Compositions for oral administration of zoledronic acid or related compounds for treating disease
BR112016024421A2 (pt) composição farmacêutica, cápsula e uso da composição farmacêutica
EP3223809A4 (en) Amino acid compositions for the treatment of symptoms of disease
BR112017020307A2 (pt) método para inibir os sintomas associados com a ingestão de álcool, e, composição farmacêutica
BR112017009510A2 (pt) composições compreendendo ciclosporina
BR112017001803A2 (pt) aril-hidrazidas contendo uma fração de 2-piridona como agentes antibacterianos seletivos
MX2016006544A (es) Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas.
BR112014018226A8 (pt) Derivados de pirimidooxazocina como inibidores de mtor

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/10/2014, OBSERVADAS AS CONDICOES LEGAIS.